Together, these data indicate that AGTR2 may function as a tumor suppressor in AML, and is transcriptionally silenced not by mutation, but through chromatin reorganization and coordinated epigenetic repression involving both Polycomb-mediated histone modification and decreased chromatin accessibility. The gene discussed is AGTR2; the disease is neoplasm.